



Orion Investor Presentation

Disclaimer

This presentation contains forward-looking statements which involve risks and uncertainty factors. These statements are not based on historical facts but relate to the Company's future activities and performance. They include statements about future strategies and anticipated benefits of these strategies.

These statements are subject to risks and uncertainties. Actual results may differ substantially from those stated in any forward-looking statement. This is due to a number of factors, including the possibility that Orion may decide not to implement these strategies and the possibility that the anticipated benefits of implemented strategies are not achieved. Orion assumes no obligation to update or revise any information included in this presentation.

All the figures in this presentation have been rounded, which is why the total sums of individual figures may differ from the total sums shown.

Content

- 1) Orion in brief
- 2) Highlights of 1-9/2022
- 3) Research & Development
- 4) Sustainability
- 5) Appendices
- 6) Financial calendar



Orion in brief

Key messages

1 Orion develops, manufactures and markets human and animal pharmaceuticals and APIs. Products marketed in >100 countries.

2 Balanced business model: Both proprietary drugs and generics.



3 Growth targeted through new in-house developed drugs.

4 Core therapy areas in R&D: pain and oncology.

5 Strong position in the Nordic generics market.

6 Strong profitability, stable dividends.

Orion at a glance (2021 figures)



Net sales **1,041** MEUR



Operating profit **243** MEUR



Personnel **3,355** (31 Dec 2021)



R&D investments **118** MEUR




7 production sites



Own sales unit in **26** European
and **5** Asia-Pacific countries


Established in **1917**

Sales by business



- Proprietary Products
- Specialty Products
- Animal Health
- Fermion & CM*

Sales by market area



- Finland
- Scandinavia
- Other Europe
- North America
- ROW

*) Contract manufacturing

Financial development between 2008 and 2021

Net sales



Operating profit




Orion's businesses



Proprietary Products

In-house developed drugs and other drugs with valid product protection for global markets. Own sales network in Europe.




37%



Specialty Products

Generic prescription drugs, OTC and non-medical products, biosimilars.

Finland	55%
Scandinavia	15%
Eastern Europe	16%
ROW	14%




49%



Animal Health

Own animal drugs for global markets. Other drugs and well-being products. Own sales network in the Nordics and Eastern Europe.




7%



Fermion & Contract manufacturing

Active pharmaceutical ingredients (APIs) for own proprietary products. CMO & CDMO services for other pharma companies.



7%

= share of Group net sales in 2021

Outlook for 2022 (published on 13 July 2022)

Net sales

Orion estimates that in 2022 net sales will be **clearly higher** than in 2021 (in 2021 net sales were EUR 1,041 million).

Operating profit

Operating profit is estimated to be **clearly higher** than in 2021 (in 2021 operating profit was EUR 243 million).



Key assumptions impacting the outlook

Net sales

- + Upfront payment
- + Nubeqa®
- + VMD acquisition
- Simdax®
- *dexdor*®

Operating profit

- + Upfront payment
- + Nubeqa®
- Simdax®
- *dexdor*®
- Cost inflation
- Price competition in generics
- Sales & marketing expenses

Orion's financial objectives



Growing net sales more rapidly than growth of the pharmaceuticals market. Achievement of this objective requires continuous investment in development of the product portfolio.



Keeping the equity ratio at least 50%.



Maintaining profitability at a good level. The aim is operating profit that exceeds 25% of net sales.



Distributing an annual dividend that in the next few years will be at least EUR 1.30 per share, and increasing the dividend in the long term.

Orion's strategic growth target to reach EUR 1.5 billion net sales by the end of 2025 expresses the above growth target in more tangible manner.

Financial targets are all important Right balance needed Relative importance of targets change over time

Key elements of Orion's growth

Proprietary
Products
and R&D



Growth drivers

Animal
Health



Support
growth

Specialty Products



Generate cash
flow to fund
growth
investments
Support growth

Fermion



APIs for R&D
and
Proprietary
Products

Defensive
industry




Less vulnerable
to
macroeconomic
volatility

Growth drivers for Orion



* Development phase molecule - requires success in clinical development and regulatory approval

Key clinical development pipeline



Oncology

Pain / neurology

¹ In collaboration with Bayer


² In collaboration with MSD

Updates vs. Q2 2022:

- Development of Easyhaler® tiotropium terminated
- ODM-105 Phase I ready
- ODM-111 entered Phase I


Orion had 79,631 shareholders on 30 September 2022

By number of shares



- Households (Finnish retail)
- Non-Finnish holders and nominee-registered
- Private corporations
- Public sector
- Non-profit institutions
- Financial and insurance corporations

By number of votes




Largest shareholders by votes and shares on 30 September 2022


#	Shareholder	% of votes	Number of votes
1	Erkki Etola and companies	6.35	50,325,000
2	Maa- ja vesitekniiikan tuki r.y. and companies	5.25	41,667,200
3	Ilmarinen Mutual Pension Insurance Company	4.87	38,613,629
4	Ylppö Jukka Arvo	3.16	25,090,449
5	Into Ylppö and commanding votes	2.01	15,952,688
6	Aho Group Oy and commanding votes	1.86	14,712,274
7	Orion Pension Fund	1.40	11,064,792
8	Eija Ronkainen and companies	1.36	10,749,615
9	Saastamoisen säätiö (foundation)	1.27	10,099,920
10	Ingman Finance Oy Ab	1.12	8,900,000
11	Elo Mutual Pension Insurance Company	0.93	7,382,000
12	Leikola Erkki	0.71	5,638,000
13	Salonen Seppo Tapani	0.69	5,433,740
14	Westerlund Riikka Maritza	0.62	4,892,700
15	Kyttilä Miika Elias Anton	0.48	3,883,240
16	Salonen Ilkka Mikael	0.44	3,490,300
17	Lenko Hanna Liisa	0.42	3,358,000
18	Kyttilä Jukka	0.39	3,078,540
19	Orion Research Foundation	0.37	2,942,434
20	Anttalainen Risto Juhani	0.35	2,759,000
	20 largest shareholders, total	34.04	269,983,521
	Other shareholders	65.96	523,050,713
	Total		793,034,234

#	Shareholder	% of shares	Number of shares
1	Ilmarinen Mutual Pension Insurance Company	2.50	3,520,629
2	Erkki Etola and companies	2.00	2,825,000
3	Maa- ja vesitekniiikan tuki r.y. and companies	1.48	2,083,360
4	Elo Mutual Pension Insurance Company	1.29	1,818,800
5	The Social Insurance Institution of Finland, KELA	1.01	1,418,368
6	Ylppö Jukka Arvo	0.99	1,394,865
7	Varma Mutual Pension Insurance Company	0.94	1,324,397
8	Into Ylppö and commanding votes	0.73	1,028,340
9	The State Pension Fund	0.71	1,000,000
10	OP Finland Fund	0.67	891,762
11	Aho Group Oy and commanding votes	0.53	745,393
12	Orion Pension Fund	0.51	724,840
13	Orion Oyj	0.50	711,272
14	Eija Ronkainen and companies	0.41	575,115
15	Saastamoisen säätiö (foundation)	0.36	504,996
16	Nordea Pro Finland Fund	0.32	452,208
17	Ingman Finance Oy Ab	0.32	445,000
18	Orion Research Foundation	0.29	415,510
19	Danske Invest Finnish Equity Fund	0.28	398,448
20	The estate of Jouko Brade and companies	0.27	379,250
	20 largest shareholders, total	16.05	22,657,553
	Other shareholders	83.95	118,476,725
	Total		141,134,278

Orion B share performance January 2016 - September 2022




Acquisition of VMD - Orion Animal Health and VMD complement each other - no overlaps



- Orion Animal Health operations
- VMD operations in Europe (+Vietnam in Asia)
- Partner and distributor network
- Own operations in 14 countries



Net sales in 2021	EUR 73 million	EUR 61 million
Personnel	72	181
Manufacturing sites	2 (Espoo, Turku)	1 (Arques)
Manufacturing & R&D focus	Companion animals	Food producing animals





Highlights in January–September 2022

An eventful year for Orion so far



Bayer updated estimate on Nubeqa's peak sales potential



Research focus on oncology and pain



Liisa Hurme appointed as President & CEO as of 1 November 2022



Orion gained rights to a potent and selective NaV 1.8 blocker for the treatment of acute and chronic pain



Acquisition of animal health company VMD (Inovet)



Orion and MSD announced a global development and commercialisation agreement for ODM-208



FDA approval for darolutamide in mHSPC

Sales developed well - milestone having material impact on net sales and operating profit

Orion

- Orion and MSD announced a global development and commercialisation agreement for ODM-208 - Upfront payment of USD 290 million of which EUR 228 million recognized in Q3 2022 net sales and operating profit
- Product sales developed well
- Costs increased clearly mainly due to the execution of the ODM-208 agreement (~EUR 20 million), increased S&M activity and timing of R&D project costs

R&D

- ODM-111 (NaV 1.8 blocker) to Phase I
- ODM-105 (tasipimidine) prepared for Phase II
- Development of Easyhaler® tiotropium terminated

Operating environment

- Cost inflation impact started to be felt
- Risks related to energy availability and price have increased throughout the supply chain

Key figures 1–9/2022 - upfront payment impacts all figures

Net sales

1,046

MEUR (765)
+37%

Operating profit

399

MEUR (203)
+96%

Operating profit
margin

38%


(27%)

Cash flow from
operating activities
per share

3.05


EUR (0.99)
+208%

Development of net sales in 1-9/2022 vs. 1-9/2021



* Nubeqa® product sales & royalty ** Proprietary Products and Specialty Products *** Animal Health, Fermion and Contract Manufacturing
 **** Without Nubeqa® royalties

Development of operating profit in 1-9/2022 vs. 1-9/2021





* Product & service sales without sales margin and product mix change and exchange rate effect



** Product sales margin and product mix change but without exchange rate effect

*** Exchange rate effect on gross margin

Geographical breakdown and development of net sales



Animal Health growing strongly due to Inovet acquisition



* Other mostly comprises the impact of translation differences on Orion's net sales.


TOP 10 products in 1-9/2022

		EUR million	vs. 1-9/2021
1.	Easyhaler® product portfolio	94	+13%
2.	Stalevo®, Comtess®, Comtan®	79	+7%
3.	Nubeqa®	53	+101%
4.	Simdax®	33	-22%
5.	Dexdomitor®, Domitor®, Domosedan®, Antisedan®	28	+6%
6.	Divina® series	20	+19%
7.	Burana®	19	+14%
8.	Solomet®	18	+15%
9.	<i>dexdor</i> ®	15	-44%
10.	Biosimilars	15	-6%
	Proprietary Products	Specialty Products	Animal Health




Proprietary Products

Nubeqa® and ODM-208 milestone driving the growth




Proprietary Products sales split 1-9/2022





* 'Others' include service sales, milestone payments and products such as Enanton®, Precedex® and pharmaceuticals sold for use in clinical trials.

Nubeqa® sales* booked by Orion showing strong growth - vary as expected from quarter to quarter





* Orion's sales to Bayer for commercial use + royalties from Bayer

Easyhaler® continued on a growth path (+13%)




Sales of Parkinson's franchise +7%




Dexdor® and Simdax® - declining as expected

Dexdor®





Simdax®






Specialty Products


Geographical split of net sales



Growth in both product segments



Sales split 1-9/2022



■ Generic drugs ■ Self-care products

In Finland, Orion's reference priced prescription drugs developed clearly better than the market

The market for reference priced prescription drugs in Finland* (1-9/2022)

MEUR **330** (353)

The sales of Orion's reference priced prescription drugs in Finland

MEUR **80** (72)

Market development

-7%

Orion's development


+11%



* The reference-priced prescription drugs group metric counts in products that were reference-priced prescription drugs at the time the statistics were compiled. For this reason, sales figure in the comparative period may deviate from previously published data.

Orion is strong in home market Finland

Human pharma market in Finland 1-9/2022
 Medicinal and non-medicinal products
 in hospital and pharmacy channels: EUR 2,254 million (+4%)



Reference priced prescription drugs

Orion market share in pharmacy

24%

(20%)*

* The reference-priced prescription drugs group metric counts in products that were reference-priced prescription drugs at the time the statistics were compiled. For this reason, the market share figure in the comparative period may deviate from previously published data.

Self-care products

Orion market share in pharmacy

26%

(25%)

Human pharmaceuticals total

Orion market share in hospital & pharmacy

11%

(11%)

Energy risk management in Orion

Orion is targeting carbon neutrality in its own operations by 2030



Systematic progress towards 2030 carbon neutrality target. For the short term, emissions may increase and the share of renewable energy may decrease.



Ensuring the availability of energy for own production and further reducing dependence on non-renewable energy sources through emission reduction measures.



External supply chain: proactive supplier management and measures to ensure continuity of production



Raising awareness: encouraging energy savings measures and lowering the indoor temperature of office buildings

Focus areas in 2022

TARGET	KPIs 2022	Status on 30 September 2022
Increasing the sales of the current product portfolio	Significant increase in sales of Nubeqa® booked by Orion	On target
	Easyhaler® product portfolio sales increase by more than 5%	On target
Building up long-term growth	In-licensing of new products	In progress
	Portfolio enhancement through product acquisitions and M&A	On target
	Partner for ODM-208 development and commercialisation	On target
	Launch of Phase III clinical trial on ODM-208*	Target not attainable
	At least one new project proceeds to clinical development	On target
	Solidifying the R&D portfolio with new collaboration agreements	On target

 On target

 In progress

 Target not attainable


 Not known

* Based on the decision to recruit additional patients to the ongoing Phase II study on ODM-208, further data from this trial is expected in 2023. Thus the target not attainable.




Research and development

Proprietary human pharmaceuticals developed by Orion



Main Orion Animal Health Marketing Authorisations



Focus areas of Orion's R&D



Medicines for humans

- In Proprietary Products the research focus in oncology and pain
- Orion develops also generic medicines



Animal Health

- Orion utilises the R&D of proprietary products to develop new medicines for animals



Fermion

- APIs for Orion's proprietary products
- Generic APIs
- Contract development for pharmaceutical companies

Together we can achieve more in R&D



Research Areas in Orion's R&D

PAIN



Ion channels and neuro-immune interaction

ONCOLOGY



Immuno-Oncology

- FiCAR T-cell therapy
- 2nd generation immune-checkpoint inhibitors




Cancer genomics and
Cell signalling



Antibody drug conjugates

Key clinical development pipeline



Oncology

Pain / neurology

¹ In collaboration with Bayer

² In collaboration with MSD

Updates vs. Q2 2022:

- Development of Easyhaler® tiotropium terminated
- ODM-105 Phase I ready
- ODM-111 entered Phase I

Orion's key clinical trials with darolutamide

Clinical trial and treatment	Indication	Primary endpoint and results	Key secondary endpoints
ARAMIS darolutamide + ADT	nmCRPC	Metastasis free survival prolongation by 22.0 months, 59% risk reduction (HR=0.41, p<0.001)	Overall survival 31% risk reduction (HR=0.69, p=0.003)
ARASENS darolutamide + ADT + docetaxel	mHSPC	Overall survival 32.5% risk reduction (HR=0.675, p<0.001)	Time to castration resistant PC 64% risk reduction (HR=0.36, p<0,001)
ARANOTE darolutamide + ADT	mHSPC	Radiological progression-free survival (study ongoing)	Overall survival (study ongoing)

Overall incidence of treatment-emergent adverse events was similar between treatment arms (darolutamide group vs. placebo group) both in ARAMIS and ARASENS trials

ADT = androgen deprivation therapy
nmCRPC = non-metastatic castration-resistant prostate cancer
mHSPC = metastatic hormone-sensitive prostate cancer

Orion develops darolutamide in collaboration with Bayer.

Global prostate cancer estimates (GLOBOCAN 2020)


2nd

most commonly
diagnosed
malignancy
in men worldwide



5th

leading cause of
death from cancer
in men



1.4

million men
diagnosed with
prostate cancer

375,000

died from
the disease




50+

Mainly affects men
over 50, the risk
increases with age

ODM-208: CYP11A1 inhibitor to treat patients with metastatic castration-resistant prostate cancer (mCRPC)

ODM-208



First-in-class oral molecule to inhibit the synthesis of all steroid hormones and precursors, which could mediate androgen receptor signalling and tumor growth.

CYPIDES Phase I

Target population: patients with prostate cancer that has become resistant to the standard hormonal treatments.

32% of the patients achieved a PSA decrease of $\geq 50\%$

68% of patients with AR LBD mutation achieved a PSA decrease of $\geq 50\%$



Sustainability is built into Orion's mission



Orion's Sustainability Agenda



Patient safety as a top priority



Patient safety has been a priority for us for a hundred years and it continues to be the cornerstone of our daily operations.

We play a significant role in ensuring reliable supply of medications - even in the wake of a crisis.



Active work for a better environment



We want to be the environmental leaders in our industry.

We continuously raise the bar in climate and environmental responsibility, and we challenge others to follow.

We are strongly heading towards achieving carbon-neutrality in our own operations by 2030.



Care for well-being professionals



We want to take care of Orionees - professionals who put their heart and expertise in everything they do.

Our workplace is inspiring. We want our people to feel well.



Ethics at the core of our business



We maintain strict ethical standards and act responsibly in all situations.

Together with our partners we are building a transparent and sustainable business.

Orion's Sustainability Agenda and indicators 2021



Patient safety as a top priority



Active work for a better environment



Care for well-being professionals



Ethics at the core of our business



Customer complaints
(pharmaceuticals)

65

Ppm (76)



GxP* audits
by Orion

256

(141)



Greenhouse gas
emissions
(scope 1&2)

20,563

tCO2e (18,611)



Energy savings
target set for
2025
achieved

114%

(53%)



Injury rate

4.8

LTIF 1 (3.6)



Code of Conduct
training, no. of
participants

653


(3,410)

*Good Practices



Appendices


Track record vs. financial objectives



Orion Diagnostica Oy was divested in 2018 and is not included in the Net sales and Operating profit figures from 2017 onwards.


Net sales and operating profit by quarter (MEUR)

Net sales



■ 2018 ■ 2019 ■ 2020 ■ 2021 ■ 2022

Operating profit



■ 2018 ■ 2019 ■ 2020 ■ 2021 ■ 2022

Quarterly net sales by unit (MEUR)

Proprietary Products



Specialty Products



Animal Health



Fermion & Contract Manufacturing



Key figures


Orion's key figures	2018	2019	2020	2021	YTD9'22	Change vs. YTD9'21
Net sales, EUR million	977.5	1,051.0	1,078.1	1,041.0	1,046.1	+36.8%
EBITDA	293.9	308.9	336.5	289.1	433.9	+83.5%
Operating profit, EUR million	252.8	252.8	280.1	243.3	398.9	+96.1%
Profit before taxes, EUR million	248.4	250.8	278.3	242.3	399.8	+97.5%
R&D expenses, EUR million	104.0	119.3	123.2	117.7	97.0	+26.5%
Equity ratio, %	68.8%	76.7%	66.7%	68.1%	62.5%	
Gearing, %	-17.1%	-17.8%	-25.4%	-14.5%	-15.7%	
ROCE (before taxes), %	44.3%	29.9%	34.8%	28.8%	52.7%	
Return on equity, %	45.5%	25.8%	29.1%	26.2%	49.3%	
Basic earnings per share, EUR	1.40	1.43	1.56	1.38	2.26	+97.4%
Interest bearing net debt	-132.1	-139.1	-185.8	-108.3	-152.2	+215.5%
Cash flow from operating activities per share, EUR				1.53	3.05	+207.6%
Dividend per share, EUR	1.50	1.50	1.50	1.50		

= includes both continuing and discontinued (Orion Diagnostica) operations


Income statement

Formation of profits, EUR million	2018	2019	2020	2021	YTD9'22	Change vs. YTD9'21
Net sales	977.5	1,051.0	1,078.1	1,041.0	1,046.1	+36,8 %
Cost of goods sold	-387.9	-417.6	-434.4	-447.5	-352.4	+8,6 %
Gross profit	589.6	633.4	643.7	593.5	693.7	+57,7 %
Other operating income and expenses	5.5	2.2	5.4	6.4	4.3	-27,7 %
Sales and marketing expenses	-195.3	-215.7	-204.3	-191.0	-151.2	+12,3 %
R&D expenses	104.0	-119.3	-123.2	-117.7	-97.0	+26,5 %
Administrative expenses	-43.0	-47.8	-41.6	-47.9	-50.9	+63,1 %
Operating profit	252.8	252.8	280.1	243.3	398.9	+96,1 %
Profit before taxes	248.4	250.8	278.3	242.3	399.8	+97,5 %
Profit for the period for continuing operations	197.3	200.4	219.9	193.8	317.9	+97,5 %
Profit for the period for discontinued operations	132.9					
Profit for the period	330.3	200.4	219.9	193.8	317.9	+97,5 %

Royalties and milestones



Development of Proprietary Products net sales




Financial position


EUR million	9/22	9/21	Change %
Non-current assets total	688.1	453.4	+51.7%
Inventories	309.1	272.6	+13.4%
Trade receivables	172.1	147.2	+16.9%
Other receivables	28.4	26.6	+6.6%
Cash & cash equivalents & money market investments	367.1	156.3	+134.9%
Current assets total	879.5	602.7	+45.9%
Assets total	1,567.5	1,056.1	+48.4%

EUR million	9/22	9/21	Change %
Equity total	971.8	743.1	+30.8%
Interest-bearing non-current liabilities	197.9	104.7	+88.9%
Non-current liabilities total	343.6	157.7	+116.5%
Current liabilities total	252.1	154.3	+63.4%
Liabilities total	595.7	313.0	+90.3%
Equity and liabilities total	1,567.5	1,056.1	+48.4%


Development of capital expenditure



Development of net working capital




- Receivables
- Inventories
- Short-term non-interest bearing liabilities
- Net Working Capital



- Receivables
- Inventories
- Short-term non-interest bearing liabilities
- Net Working Capital

Dividend distribution policy and dividend history

- Orion's dividend distribution takes into account distributable funds and capital expenditure and other financial requirements in medium and long term to achieve the financial objectives.



* Change in dividend payout ratio is due to higher EPS (EUR 2.35) which is explained by the divestment of Orion Diagnostica

Easyhaler® - One device with several therapy options for patients with asthma or Chronic Obstructive Pulmonary Disease (COPD)

- Easyhaler® portfolio consists of 6 dry-powder inhaler (DPI) products with several well-known generic active substances for the treatment of patients with asthma or COPD.



Carbon
Neutral
Product



- Key benefits:

- Wide range of different therapies administered from one type of DPI
- Easy and quick to teach, learn and use
- High accuracy and consistency of dosing *even with low inhalation capacity*
- Fully carbon neutral product range *supporting sustainability goals of Orion*



Upcoming events

Financial Statement Release for 2022	9/2/2023
AGM planned to be held	22/3/2023
Interim Report 1-3/2023	27/4/2023
Half-Year Financial Report	17/7/2023
Interim Report 1-9/2023	26/10/2023



Investor Relations

Jari Karlson

CFO

jari.karlson@orion.fi

+358 10 426 2883

Tuukka Hirvonen

Head of Investor Relations

tuukka.hirvonen@orion.fi

+358 10 426 2721

Paula Bäck

Executive Assistant

(Investor meeting requests)

paula.back@orion.fi

+358 10 426 3011

www.orion.fi/EN/Investors

twitter.com/OrionCorplR